Research progress in targeted therapy for peripheral T-cell lymphoma

doi:10.3760/cma.j.cn371439-20260315-00109

Abstract

Abstract:

Peripheral T-cell lymphoma （PTCL） is a heterogeneous group of malignant tumors originating from post-thymic mature T cells and natural killer cells， encompassing multiple subtypes， almost all of which exhibit high aggressiveness. Currently， the first-line treatment for PTCL patients still follows the therapeutic regimen for aggressive B-cell lymphoma， but the efficacy duration is short and the adverse effects are severe， with an overall 5-year survival rate of only approximately 30%， indicating a poor prognosis. In recent years， with the advancement of molecular genetics and epigenetics， novel targeted drugs have emerged continuously and demonstrated good efficacy and safety profile in various clinical studies. Combination therapies of new drugs are expected to overcome the efficacy limitations of monotherapy. To explore and summarize the latest research progress and clinical prospects of targeted therapy for PTCL， which can provide a basis for clinical decision-making of targeted therapy for PTCL.

Key words: Lymphoma, T-cell, peripheral, Molecular targeted therapy, Clinical trial

Han Mingming, Qiao Qiqi, Yin Xia, Xing Lijie, Liu Dan. Research progress in targeted therapy for peripheral T-cell lymphoma[J]. Journal of International Oncology, 2026, 53(11): 699-704.

References 49

[1]	Mina A, Pro B. T time: emerging and new therapies for peripheral T-cell lymphoma[J]. Blood Rev, 2022, 52: 100889. DOI: 10.1016/j.blre.2021.100889.
[2]	Angelos M, Ballard H, Barta S. Advances and personalized approaches in the frontline treatment of T-cell lymphomas[J]. J Pers Med, 2022, 12(2): 267. DOI: 10.3390/jpm12020267.
[3]	Moskowitz AJ, Stuver RN, Horwitz SM. Current and upcoming treatment approaches to common subtypes of PTCL (PTCL, NOS; ALCL; and TFHs)[J]. Blood, 2024, 144(18): 1887-1897. DOI: 10.1182/blood.2023021789. pmid: 38306597
[4]	Dreger P, Schmitz N. The role of stem cell transplant (auto and allo) in PTCL and CTCL[J]. Hematology Am Soc Hematol Educ Program, 2024, 2024(1): 69-77. DOI: 10.1182/hematology.2024000670. pmid: 39644016
[5]	Pichler AS, Amador C, Fujimoto A, et al. Advances in peripheral T cell lymphomas: pathogenesis, genetic landscapes and emerging therapeutic targets[J]. Histopathology, 2024, 86(1): 119-133. DOI: 10.1111/his.15376.
[6]	Huang YH, Qiu YR, Zhang QL, et al. Genomic and transcriptomic profiling of peripheral T cell lymphoma reveals distinct molecular and microenvironment subtypes[J]. Cell Rep Med, 2024, 5(2): 101416. DOI: 10.1016/j.xcrm.2024.101416.
[7]	Ma S, Li S, Zuo X, et al. Clinicopathologic analysis of nodal T-follicular helper cell lymphomas, a multicenter retrospective study from China[J]. Front Immunol, 2024, 15: 1371534. DOI: 10.3389/fimmu.2024.1371534.
[8]	Lone WG, Yu J, Liu XX, et al. Cooperative role of distinctive TP53 and PTEN combined loss in the peripheral T cell lymphoma-GATA3 molecular subgroup[J]. Sci Adv, 2025, 11(42): eadx6877. DOI: 10.1126/sciadv.adx6877.
[9]	Horwitz S, O'Connor O A, Pro B, et al. The ECHELON-2 trial: 5-year results of a randomized, phase Ⅲ study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma[J]. Ann Oncol, 2022, 33(3):288-298. DOI: 10.1016/j.annonc.2021.12.002.
[10]	Song Y, Malpica L, Cai QQ, et al. Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study[J]. Lancet Oncol, 2024, 25(1): 117-125. DOI: 10.1016/s1470-2045(23)00589-2. pmid: 38092009
[11]	Wu D, Shi YX, Zhang H, et al. Epigenetic mechanisms of immune remodeling in sepsis: targeting histone modification[J]. Cell Death Dis, 2023, 14(2): 112. DOI: 10.1038/s41419-023-05656-9. pmid: 36774341
[12]	Irimia R, Piccaluga PP. Histone deacetylase inhibitors for peripheral T-cell lymphomas[J]. Cancers (Basel), 2024, 16(19): 3359. DOI: 10.3390/cancers16193359.
[13]	Lu G, Jin SK, Lin SW, et al. Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL)[J]. Clin Epigenetics, 2023, 15(1): 124. DOI: 10.1186/s13148-023-01531-8. pmid: 37533111
[14]	Cao HY, Li L, Xue SL, et al. Chidamide: targeting epigenetic regulation in the treatment of hematological malignancy[J]. Hematol Oncol, 2022, 41(3): 301-309. DOI: 10.1002/hon.3088.
[15]	Li Z, Sun P, Yang H, et al. 810MO combination of mitoxantrone hydrochloride liposome with chidamide in patients with relapsed or refractory peripheral T cell lymphoma: a phase Ⅰ/Ⅱ study[J]. Ann Oncol, 2024, 35(Suppl 2): S600. DOI: 10.1016/j.annonc.2024.08.861.
[16]	Li Z, Sun P, Ding KY, et al. Combination of mitoxantrone hydrochloride liposome with chidamide in patients with relapsed or refractory peripheral T cell lymphoma: updated results of the phase Ⅱ study[J]. Blood, 2025, 146(Suppl 1): 3639. DOI: 10.1182/blood-2025-3639.
[17]	Khan N, Dahi PB, Khimani F, et al. Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphoma[J]. Blood Adv, 2025, 9(18): 4687-4692. DOI: 10.1182/bloodadvances.2024014263. pmid: 40179392
[18]	Kalac M, Jain S, Tam CS, et al. Real-world experience of combined treatment with azacitidine and romidepsin in patients with peripheral T-cell lymphoma[J]. Blood Adv, 2023, 7(14): 3760-3763. DOI: 10.1182/bloodadvances.2022009445. pmid: 36790924
[19]	Yang LY, Qiu Q, Wang J, et al. Preclinical and first-in-human of purinostat mesylate, a novel selective HDAC Ⅰ/Ⅱb inhibitor, in relapsed/refractory multiple myeloma and lymphoma[J]. Signal Transduct Target Ther, 2025, 10: 201. DOI: 10.1038/s41392-025-02285-w.
[20]	Niu T, Liu L, Wu HJ, et al. High HDAC Ⅰ/Ⅱb selective inhibitor purinostat mesylate in relapsed and refractory peripheral T-cell lymphoma: a single-agent phase Ⅱa study[J]. Blood, 2025, 146(Suppl 1): 5415. DOI: 10.1182/blood-2025-5415.
[21]	Aguilar R, Rosenberg M, Levy V, et al. An evolving landscape of PRC2-RNA interactions in chromatin regulation[J]. Nat Rev Mol Cell Biol, 2025, 26(8): 631-642. DOI: 10.1038/s41580-025-00850-3.
[22]	Wozniak M, Czyz M. Exploring oncogenic roles and clinical significance of EZH2: focus on non-canonical activities[J]. Ther Adv Med Onco, 2025, 17: 17588359241306026. DOI: 10.1177/1758835924 1306026.
[23]	Liu YK, Yang Q. The roles of EZH2 in cancer and its inhibitors[J]. Med Oncol, 2023, 40(6): 167. DOI: 10.1007/s12032-023-02025-6. pmid: 37148376
[24]	Dou FZ, Tian ZX, Yang X, et al. Valemetostat: first approval as a dual inhibitor of EZH1/2 to treat adult T-cell leukemia/lymphoma[J]. Drug Discov Ther, 2022, 16(6): 297-299. DOI: 10.5582/ddt.2022.01085.
[25]	Zinzani PL, Izutsu K, Mehta-Shah N, et al. Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE- PTCL01): a multicentre, open-label, single-arm, phase 2 study[J]. Lancet Oncol, 2024, 25(12): 1602-1613. DOI: 10.1016/s1470-2045(24)00503-5. pmid: 39486433
[26]	Hong HM, Chen ZG, Zhang MZ, et al. A multicenter, open-label, single-arm, phase Ⅰb clinical trial of HH2853 treatment in patients with relapsed and/or refractory peripheral T-cell lymphoma[J]. J Hematol Oncol, 2025, 18(1): 50. DOI: 10.1186/s13045-025-01697-z.
[27]	Krug A, Tari G, Saidane A, et al. Novel T follicular helper-like T-cell lymphoma therapies: from preclinical evaluation to clinical reality[J]. Cancers, 2022, 14(10): 2392. DOI: 10.3390/cancers14102392.
[28]	Collins NB, Al Abosy R, Miller BC, et al. PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment[J]. J Immunother Cancer, 2022, 10(3): e003402. DOI: 10.1136/jitc-2021-003402.
[29]	付瑛, 王华庆. PI3K抑制剂在淋巴瘤治疗中的现状和挑战[J]. 国际肿瘤学杂志, 2024, 51(10): 660-666. DOI: 10.3760/cma.j.cn371439-20240407-00111.
[30]	Mehta-Shah N, Zinzani PL, Jacobsen ED, et al. Duvelisib in patients with relapsed/refractory peripheral T-cell lymphoma: final results from the phase 2 PRIMO trial[J]. Blood, 2024, 144(Suppl 1): 3061. DOI: 10.1182/blood-2024-203577.
[31]	Horwitz SM, Nirmal AJ, Rahman J, et al. Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial[J]. Nat Med, 2024, 30(9): 2517-2527. DOI: 10.1038/s41591-024-03076-6. pmid: 38886623
[32]	Ford JG, Koh MJ, Lenart AW, et al. Real-world evidence of duvelisib and romidepsin in relapsed/refractory peripheral and cutaneous T-cell lymphomas[J]. Blood Adv, 2025, 9(16): 4286-4305. DOI: 10.1182/bloodadvances.2025016347. pmid: 40526834
[33]	Jin J, Cen H, Zhou KS, et al. A phase Ⅰb Study of linperlisib in the treatment of patients with relapsed and/or refractory peripheral T-cell lymphoma[J]. Clin Cancer Res, 2024, 30(20): 4593-4600. DOI: 10.1158/1078-0432.Ccr-24-1194.
[34]	Chu MQ, Zhang TJ, Yang Q, et al. Successful treatment of an elderly patient with relapsed/refractory angioimmunoblastic T-cell lymphoma with the PI3Kδ inhibitor linperlisib: a case report[J]. Front Pharmacol, 2025, 16: 1554501. DOI: 10.3389/fphar.2025.1554501.
[35]	Wei JY, Yu WJ, Tong HY, et al. Dual CK1ε/PI3Kδ inhibitor HZ-H08905, exhibits as a potential therapeutic strategy for hematologic malignancies[J]. Blood, 2022, 140(Suppl 1): 12065. DOI: 10.1182/blood-2022-165195.
[36]	Wei JY, Yu WJ, Jin ZM, et al. Preliminary efficacy and safety of the CK1ε/PI3Kδ dual inhibitor HZ-H 08905 in patients with relapsed and/or refractory peripheral T-cell lymphomas: results from the phase 1 HZ-H08905-101 study[J]. Blood, 2024, 144(Suppl 1): 3057. DOI: 10.1182/blood-2024-201210.
[37]	Ott N, Faletti L, Heeg M, et al. JAKs and STATs from a clinical perspective: loss-of-function mutations, gain-of-function mutations, and their multidimensional consequences[J]. J Clin Immunol, 2023, 43(6): 1326-1359. DOI: 10.1007/s10875-023-01483-x. pmid: 37140667
[38]	Wang YH, Wang Z, Li SY, et al. Deciphering JAK/STAT signaling pathway: a multifaceted approach to tumorigenesis, progression and therapeutic interventions[J]. Int Immunopharmacol, 2024, 131: 111846. DOI: 10.1016/j.intimp.2024.111846.
[39]	Song YQ, Malpica L, Cai QQ, et al. Golidocitinib in treating refractory or relapsed peripheral T-cell lymphoma: full analysis of the multinational pivotal study results (JACKPOT8)[J]. Blood, 2023, 142(Suppl 1): 305. DOI: 10.1182/blood-2023-172962.
[40]	Song Y, Yoon DH, Yang H, et al. Phase Ⅰ dose escalation and expansion study of golidocitinib, a highly selective JAK1 inhibitor, in relapsed or refractory peripheral T-cell lymphomas[J]. Ann Oncol, 2023, 34(11): 1055-1063. DOI: 10.1016/j.annonc.2023.08.013. pmid: 37673210
[41]	Jin J, Cai QQ, Zhang LL, et al. Phase 2 study of golidocitinib, a JAK1 selective inhibitor, as maintenance therapy in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26)[J]. Blood, 2023, 142(Suppl 1): 4430. DOI: 10.1182/blood-2023-185543.
[42]	Qin Y, Xia PH, Huang YH, et al. Serum free fatty acid promotes tumor progression and predicts golidocitinib sensitivity in peripheral T-cell lymphoma[J]. Blood Adv, 2026, 10(7): 2125-2141. DOI: 10.1182/bloodadvances.2025017682.
[43]	Hamasy A, Hussain A, Mohammad DK, et al. Differential regulatory effects of the N-terminal region in SYK-fusion kinases reveal unique activation-inducible nuclear translocation of ITK-SYK[J]. Sci Rep, 2025, 15: 814. DOI: 10.1038/s41598-024-83962-8.
[44]	Horwitz SM, Feldman TA, Ye JC, et al. Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma[J]. Leuk Lymphoma, 2025, 66(6): 1100-1110. DOI: 10.1080/10428194.2025.2455489.
[45]	Hasegawa G, Nakagawa N, Ueda Y, et al. Retreatment with brentu-ximab vedotin for discordant peripheral T-cell lymphomas[J]. Leuk Res Rep, 2025, 23: 100500. DOI: 10.1016/j.lrr.2025.100500.
[46]	Weber T, Denker S, Helmes JJ, et al. Brentuximab vedotin plus DHAP as effective salvage therapy in CD30⁺ peripheral T-cell lymphoma: a retrospective multicenter study[J]. Blood, 2025, 146(Suppl 1): 5425. DOI: 10.1182/blood-2025-5425.
[47]	Lee A, Kim Y, Khodadoust M, et al. Abstract 514: correlation of sTNFR2 elevation and disease progression in cutaneous T cell lymphomas[J]. Cancer Res, 2022, 82(12_Suppl): 514. DOI: 10.1158/1538-7445.Am2022-514.
[48]	Rohrberg KS, Papai Z, Eefsen RL, et al. 19-BI-1808-01, a phase 1/2a clinical trial of BI-1808, a tumor necrosis factor receptor 2 (TNFR2) blocker/depleter with or without pembrolizumab[J]. J Clin Oncol, 2024, 42(16_suppl): 2641. DOI: 10.1200/JCO.2024.42.16_suppl.2641.
[49]	Barta S, Querfeld C, Lim S, et al. BI-1808, a tumor necrosis factor receptor 2 (TNFR2) blocker/depleter, showing promising efficacy in T cell lymphoma patients[J]. Blood, 2025, 146(Suppl 1): 3633. DOI: 10.1182/blood-2025-3633.